It is unclear whether the outcome of status epilepticus (SE), a neurological emergency associated with high mortality and morbidity, has changed over the past decade. We investigated the difference in prognosis (mortality, functional status at discharge) after adult SE episodes in a large registry between 2 time points (the years 2009 and 2017), exploring factors potentially associated with outcome, with particular attention to use of newer antiepileptic drugs (AEDs). Newer AEDs were more often prescribed in SE episodes in 2017 (80.2% vs 38.5%, P < .001); this independently correlated with year of observation, SE refractoriness, nonconvulsive SE forms, and number of AEDs. We observed a higher proportion of deterioration from baseline conditions in 2017 (67.7% vs 42.3%, P < .001), which was independently associated with, among other variables, use of newer AEDs (odds ratio = 2.91, 95% confidence interval = 1.13-7.48), whereas mortality seemed more stable over time (16.1% vs 6.3%, P = .08) without any relationship with newer AEDs. These observations suggest that newer AEDs might affect functional status but not mortality. Further investigations are necessary to improve therapeutic strategies, which currently rely on weak evidence.
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| INTRODUCTION
Status epilepticus (SE) is a neurological emergency, with an estimated yearly incidence of 20-41 per 100 000 people, and a mortality rate between 9% and 39%.
1,2 Some studies have highlighted a reduction of mortality in the past decade, hypothesizing that this could be a consequence of a prompter recognition of nonconvulsive SE and earlier, more aggressive, and more effective treatment. 3, 4 Conversely, other analyses have found a stable mortality rate 5 and even an increasing number of patients with new morbidity at hospital discharge. 5, 6 Although this may also reflect higher prevalence of nonconvulsive SE, especially in comatose patients, it might be at least partly related to therapeutic strategies. 7 Current SE treatment guidelines rely on a weak evidence beyond the first-line treatment (benzodiazepines), 8 and this leaves unanswered questions regarding the impact of antiepileptic treatment on outcome, including the role of newer antiepileptic drugs (AEDs). The aim of the present study was to assess the differences in terms of mortality and functional outcome after SE at 2 relatively distant time points, with particular attention to the use of newer AEDs.
| MATERIALS AND METHODS

| Study population
In this retrospective cohort study, we analyzed our prospective SE registry at 2 time points: the years 2009 and 2017. The registry, which has been previously described 2, 6, 9 and was approved by our ethics commission, includes consecutive adults (>16 years old) with SE treated at our hospital, excluding postanoxic causes. SE is defined as continuous seizures, or ≥2 discrete seizures with incomplete recovery, lasting >5 minutes, requiring electroencephalography (EEG) for nonconvulsive episodes.
| Variables
For each episode, the registry reports demographics, etiology classified as "potentially fatal" if leading to death independently of SE (namely, acute severe ischemic stroke or cerebral hemorrhage, acute severe craniocerebral trauma, acute central nervous system or severe systemic infection, malignant brain tumor, acquired immunodeficiency syndrome with cerebral complications, systemic or cerebral vasculitis, renal insufficiency requiring dialysis, severe metabolic disturbance, acute intoxication or alcohol withdrawal syndrome causing coma, eclampsia, advanced dementia, and intracranial tumor surgery), 10 history of previous seizures, SE duration (with an arbitrary threshold of 30 minutes for analysis), latency to treatment (threshold = 1 hour), type and number of AEDs prescribed, and need of therapeutic coma. We labeled as "newer" AEDs marketed after 1990, and classified SE as refractory if the episode required >2 treatments (first and second lines). The need of therapeutic coma and mechanical intubation, as well as the Status Epilepticus Severity Score (STESS), a validated tool for assessing SE gravity based on age, history of previous seizures, worst seizure type, and impairment of consciousness at onset, 10 were prospectively assessed. Mortality and functional outcome, defined as return to baseline status or new morbidity (namely new neurological impairment with respect to the pre-SE condition), were assessed at discharge. For this analysis, using our computerized charts, we retrospectively scored comorbidities using the Charlson Comorbidity Index (CCI), taking into account all preexisting diseases, apart from the SE cause, 11 length of acute hospital stay, and requirement of intensive care unit (ICU) treatment.
| Statistical analysis
We first explored variables associated with years of observation (ie, 2009, 2017), and then variables associated with use of newer AEDs. Finally, we tested the association of use of newer AEDs and other variables with mortality and return to baseline conditions. Differences between groups were assessed by 2-sided t tests, Mann-Whitney U tests, v 3 | RESULTS
| Demographics and clinical characteristics
We examined 78 SE episodes (64 patients) in 2009 and 96 (87 patients) in 2017, after excluding 2 episodes in the 2009 group for missing data. Table 1 illustrates demographic features and clinical variables stratified by year. Mean age was comparable in the 2 groups, whereas male gender predominated in 2017. In univariate analyses, in 2017 there were fewer short SE episodes, a higher number of AEDs, higher prescription of newer AEDs, higher prevalence of refractory SE, and higher ICU hospitalization. Conversely, need of therapeutic coma, history of previous seizures, consciousness, STESS, and CCI showed no significant differences. Table 2 shows clinical variables according to the use of any newer AEDs for a given SE episode. In the multivariate assessment (which showed an excellent goodness of fit, P = .324), this was independently associated with lack of generalized convulsive semiology, SE refractoriness, SE duration > 30 minutes, AEDs number, and year.
| Use of newer AEDs
| Outcome
Overall, deterioration from baseline clinical condition occurred in 56.3% (98 of 174 episodes) and mortality in 11.9% (18 of 151 patients). Across the 2 time periods, lack of return to pre-SE conditions occurred more frequently in 2017 (67.7% vs 42.3%, P < .001), whereas mortality showed no statistical difference (16.1% vs 6.3%, P = .08). Table S1 illustrates variables stratified for lack of return to clinical condition at discharge and mortality, respectively. The former was independently associated with lack of previous seizures, potentially fatal etiology, nonconvulsive semiology, SE refractoriness, and use of newer AEDs, after adjustment for the year of observation (excellent goodness of fit, P = .610). Mortality was independently related to increasing age, potentially fatal etiology, nonconvulsive semiology, and severe consciousness impairment (excellent goodness of fit, P = .981). Of note, use of newer AEDs was not significant.
| DISCUSSION
This study, which to the best of our knowledge is the first investigating factors related to use of newer AEDs in SE and its impact on prognosis, confirms an increase in their use over time, and its independent relationship with the recent year of observation, SE forms other than generalized convulsive, SE refractoriness, and increasing number of AEDs. Newer AEDs are independently associated with lack of return to baseline conditions at discharge (the prevalence of which increases over time), whereas mortality is unaffected.
Our group already observed an increasing prescription of newer AEDs in SE, 6 and a higher rate of failures in terminating SE using levetiracetam (LEV) rather than valproate as second-line treatment, even if without impact on mortality. 9 Moreover, a recent randomized double-blind trial revealed no better efficacy on convulsive SE when adding LEV to clonazepam as first-line prehospital treatment. 12 In the present study, we also observe an increasing prescription of AEDs over time, and increasing use of newer AEDs seems strongly associated with it, and with SE refractoriness. This might suggest that the ease of administration of newer AEDs (infusion pace and tolerance) might lead to a relative overtreatment, with a succession of medications being loaded over a few hours. Also, increasing use of extended EEGs and EEG monitoring in nonconvulsive SE over the assessed period was recently shown to be associated with a tendency toward overtreatment. 13 The maintenance of this polytherapy during the hospital stay could subsequently contribute to adverse events impacting on neurological recovery. This increased treatment may not be, on its own, beneficial regarding the overall outcome, as SE can show a delayed response to treatment.
14 It remains to be determined why newer AEDs were less often prescribed in generalized convulsive SE.
Functional outcome appears to worsen across the analyzed time periods, as previously observed. 6 It is unlikely that this reflects information bias following shorter acute stays, as hospitalization length was somewhat longer in 2017. The relationship with de novo SE episodes, severe etiology, and SE refractoriness reflects previous observations. 15, 16 Generalized convulsive semiology seems somewhat protective, probably because nonconvulsive SE is, conversely, a heterogeneous condition with potentially severe forms (especially in coma). 17 The independent association of prescription of newer AEDs with worse functional outcome, even after adjustment for the year of observation, is intriguing and deserves further exploration. This may suggest that at least some newer compounds may prove initially less efficacious than traditional ones (see above); mortality-a solid, nondebatable endpoint-is not affected. Of note, the number of compounds was not related to the outcome in multivariate analysis. Stable SE mortality has been found in US national surveys from 1999 to 2010 4 and from 1979 to 2010. 5 Conversely, in the UK it has been argued that prompter recognition and consequent SE treatment may lead to improvement of functional outcome and reduction of mortality. 3 Our study confirms that mortality appears relatively stable over time, that it is robustly associated with known SE outcome predictors such as age, etiology, and Our study has limitations. First, it is a retrospective analysis; however, the vast majority of data, especially regarding AEDs, was based on a prospective registry with uniform collection and the same author homogenously retrieved retrospective data, thus reducing the possible confounding factors. Nevertheless, data about exact timing of AED delivery was missing; merely the sequence of the prescribed medications was available. Similarly, impairment of consciousness was only evaluated at the onset of SE, and the moment of return to previous consciousness was not recorded in the registry. Second, it was conducted in a single third-level center; a selection bias may be present, although this seems unlikely because SE is habitually treated in large hospitals. We believe therefore that our results are generalizable, as the overall mortality and patient profile appear to be in line with other hospital-based series. 7, 18 Third, we did not assess treatment adequacy in respect to current guidelines, as this does not seem to influence outcome. 15 Fourth, functional outcome was evaluated at discharge, at irregular time points across patients; an information bias might be present because neurological condition may change overtime. Finally, our study is inherently limited to the analyzed time lapse; we tried to adjust our multivariate calculations to the most relevant known outcome predictors, including the year of treatment, but it is not possible to exclude formally that other unrecognized factors, such as evolving neurocritical care and EEG monitoring practices, were not at play. We nevertheless believe that the possible effect of treatment on functional status at discharge, if confirmed in other settings, may have relevant clinical repercussions.
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